{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:47:15Z","timestamp":1782334035065,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"T\u00f8mrermester J\u00f8rgen Holm og hustru Elisa f. Hansens Mindelegat","award":["20006-1937"],"award-info":[{"award-number":["20006-1937"]}]},{"DOI":"10.13039\/501100008274","name":"P. A. Messerschmidt og Hustrus Fond","doi-asserted-by":"publisher","award":["028077-0006 jhw\/mkol"],"award-info":[{"award-number":["028077-0006 jhw\/mkol"]}],"id":[{"id":"10.13039\/501100008274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NEYE-Fonden","award":["NEYE-Fonden"],"award-info":[{"award-number":["NEYE-Fonden"]}]},{"DOI":"10.13039\/501100010347","name":"Fabrikant Einar Willumsens Mindelegat","doi-asserted-by":"publisher","award":["500028"],"award-info":[{"award-number":["500028"]}],"id":[{"id":"10.13039\/501100010347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"H\u00f8jmoseg\u00e5rdlegatet","award":["2017-1064\/7"],"award-info":[{"award-number":["2017-1064\/7"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Tumour perfusion is a universal cancer biomarker with potential value in characterising primary prostate tumours and longitudinal measurements for evaluation of treatment response. To evaluate whether a change in perfusion is significant, the reproducibility of the measurement must be known. [\n                      <jats:sup>15<\/jats:sup>\n                      O]H\n                      <jats:sub>2<\/jats:sub>\n                      O positron emission tomography (PET) is the gold standard for non-invasive quantitative perfusion imaging, however repeatability data on prostate cancer are currently unavailable. Hence, the aim of the present study is to determine the repeatability of [\n                      <jats:sup>15<\/jats:sup>\n                      O]H\n                      <jats:sub>2<\/jats:sub>\n                      O tumour perfusion in prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen well-defined MRI PI-RADS lesions from ten patients were studied. The repeatability of [\n                      <jats:sup>15<\/jats:sup>\n                      O]H\n                      <jats:sub>2<\/jats:sub>\n                      O K\n                      <jats:sub>1<\/jats:sub>\n                      was 30% using both parametric image calculation and volume of interest (VOI)-based analysis. Intraclass correlation coefficient (ICC) was 0.89 and 0.91 for parametric image calculation and VOI-based analysis, respectively. A study sample size of 10 patients should be sufficient for detecting a relative change of 20% over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>15<\/jats:sup>\n                      O]H\n                      <jats:sub>2<\/jats:sub>\n                      O tumour perfusion in localised prostate cancer can be measured with a high repeatability, showing comparable performance when using parametric K\n                      <jats:sub>1<\/jats:sub>\n                      perfusion maps and VOI-based analysis. For longitudinal evaluation, changes above 30% are likely to represent actual changes in tumour perfusion, for example as response to a specific treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01375-2","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:54:33Z","timestamp":1767909273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repeatability of tumour perfusion measurement with [15O]H2O PET in prostate cancer"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7676-2322","authenticated-orcid":false,"given":"Mads Ry\u00f8","family":"Jochumsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"S\u00f6rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana Louise","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Haislund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bouchelouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Poulsen","family":"Tolbod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"6","key":"1375_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1053\/j.semnuclmed.2020.07.001","volume":"50","author":"GB Johnson","year":"2020","unstructured":"Johnson GB, Harms HJ, Johnson DR, Jacobson MS. Pet imaging of tumor perfusion: a potential cancer biomarker? Semin Nucl Med. 2020;50(6):549\u201361.","journal-title":"Semin Nucl Med"},{"key":"1375_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04998-2","author":"MR Jochumsen","year":"2020","unstructured":"Jochumsen MR, S\u00f6rensen J, Pedersen BG, Nyengaard JR, Krag SRP, Fr\u00f8ki\u00e6r J, et al. Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)\/K(+)-ATPase-density. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04998-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1375_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00757-y","volume":"11","author":"MR Jochumsen","year":"2021","unstructured":"Jochumsen MR, S\u00f6rensen J, Tolbod LP, Pedersen BG, Fr\u00f8ki\u00e6r J, Borre M, et al. Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness. EJNMMI Res. 2021;11(1):12.","journal-title":"EJNMMI Res"},{"issue":"8","key":"1375_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2967\/jnumed.118.219188","volume":"60","author":"MR Jochumsen","year":"2019","unstructured":"Jochumsen MR, Tolbod LP, Pedersen BG, Nielsen MM, Hoyer S, Frokiaer J, et al. Quantitative tumor perfusion imaging with (82)Rb PET\/CT in prostate cancer: analytic and clinical Validation. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2019;60(8):1059\u201365.","journal-title":"Soc Nuclear Med"},{"issue":"5","key":"1375_CR5","first-page":"292","volume":"8","author":"LP Tolbod","year":"2018","unstructured":"Tolbod LP, Nielsen MM, Pedersen BG, Hoyer S, Harms HJ, Borre M, et al. Non-invasive quantification of tumor blood flow in prostate cancer using (15)O-H2O PET\/CT. Am J Nucl Med Mol Imaging. 2018;8(5):292\u2013302.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"2","key":"1375_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S1536-1632(03)00039-8","volume":"5","author":"KA Kurdziel","year":"2003","unstructured":"Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, et al. Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Mol Imaging Biology: MIB : Official Publication Acad Mol Imaging. 2003;5(2):86\u201393.","journal-title":"Mol Imaging Biology: MIB : Official Publication Acad Mol Imaging"},{"issue":"6","key":"1375_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00280-002-0517-4","volume":"50","author":"TF Logan","year":"2002","unstructured":"Logan TF, Jadali F, Egorin MJ, Mintun M, Sashin D, Gooding WE, et al. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase i trial. Cancer Chemother Pharmacol. 2002;50(6):433\u201344.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1375_CR8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2967\/jnumed.114.151894","volume":"56","author":"M Lubberink","year":"2015","unstructured":"Lubberink M, Golla SS, Jonasson M, Rubin K, Glimelius B, Sorensen J, et al. (15)O-water PET study of the effect of Imatinib, a selective platelet-derived growth factor receptor inhibitor, versus Anakinra, an IL-1R antagonist, on water-perfusable tissue fraction in colorectal cancer metastases. J Nucl Med. 2015;56(8):1144\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"1375_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/2191-219X-2-31","volume":"2","author":"AM Scott","year":"2012","unstructured":"Scott AM, Mitchell PL, O\u2019Keefe G, Saunder T, Hicks RJ, Poon A, et al. Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. EJNMMI Res. 2012;2(1):31.","journal-title":"EJNMMI Res"},{"issue":"27","key":"1375_CR10","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1200\/JCO.2007.15.4385","volume":"26","author":"LK Dunnwald","year":"2008","unstructured":"Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26(27):4449\u201357.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1375_CR11","first-page":"1806","volume":"44","author":"DA Mankoff","year":"2003","unstructured":"Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2003;44(11):1806\u201314.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"issue":"5","key":"1375_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1053\/j.semnuclmed.2023.08.002","volume":"54","author":"R Slart","year":"2024","unstructured":"Slart R, Martinez-Lucio TS, Boersma HH, Borra RH, Cornelissen B, Dierckx R, et al. [(15)O]H(2)O PET: potential or essential for molecular imaging? Semin Nucl Med. 2024;54(5):761\u201373.","journal-title":"Semin Nucl Med"},{"issue":"11","key":"1375_CR13","first-page":"1784","volume":"41","author":"MA Lodge","year":"2000","unstructured":"Lodge MA, Carson RE, Carrasquillo JA, Whatley M, Libutti SK, Bacharach SL. Parametric images of blood flow in oncology PET studies using [15O]water. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2000;41(11):1784\u201392.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"issue":"10","key":"1375_CR14","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2967\/jnumed.108.052076","volume":"49","author":"MA Lodge","year":"2008","unstructured":"Lodge MA, Jacene HA, Pili R, Wahl RL. Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008;49(10):1620\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"1375_CR15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2967\/jnumed.110.079137","volume":"51","author":"AA van der Veldt","year":"2010","unstructured":"van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET\/CT scanner: test-retest variability in lung cancer. J Nucl Med. 2010;51(11):1684\u201390.","journal-title":"J Nucl Med"},{"issue":"1","key":"1375_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13550-019-0529-2","volume":"9","author":"MR Jochumsen","year":"2019","unstructured":"Jochumsen MR, Bouchelouche K, Nielsen KB, Frokiaer J, Borre M, Sorensen J, et al. Repeatability of tumor blood flow quantification with (82)Rubidium PET\/CT in prostate cancer - a test-retest study. EJNMMI Res. 2019;9(1):58.","journal-title":"EJNMMI Res"},{"issue":"5","key":"1375_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00259-011-1730-3","volume":"38","author":"HJ Harms","year":"2011","unstructured":"Harms HJ, Knaapen P, de Haan S, Halbmeijer R, Lammertsma AA, Lubberink M. Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET\/CT scanner. Eur J Nucl Med Mol Imaging. 2011;38(5):930\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"1375_CR18","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1007\/s00259-024-06799-3","volume":"51","author":"MR Jochumsen","year":"2024","unstructured":"Jochumsen MR, Christensen NL, Iversen P, Gormsen LC, S\u00f8rensen J, Tolbod LP. Whole-body parametric mapping of tumour perfusion in metastatic prostate cancer using long axial field-of-view [(15)O]H(2)O PET. Eur J Nucl Med Mol Imaging. 2024;51(13):4134\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1375_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/096228029900800204","volume":"8","author":"JM Bland","year":"1999","unstructured":"Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135\u201360.","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"1375_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"11","key":"1375_CR21","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2967\/jnumed.108.053454","volume":"49","author":"AJ de Langen","year":"2008","unstructured":"de Langen AJ, Lubberink M, Boellaard R, Spreeuwenberg MD, Smit EF, Hoekstra OS, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med. 2008;49(11):1763\u20138.","journal-title":"J Nucl Med"},{"issue":"1093","key":"1375_CR22","first-page":"20170955","volume":"92","author":"VS Hughes","year":"2019","unstructured":"Hughes VS, Wiggins JM, Siemann DW. Tumor oxygenation and cancer therapy-then and now. Br J Radiol. 2019;92(1093):20170955.","journal-title":"Br J Radiol"},{"key":"1375_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00010","volume":"7","author":"F Colliez","year":"2017","unstructured":"Colliez F, Gallez B, Jordan BF. Assessing tumor oxygenation for predicting outcome in radiation oncology: a review of studies correlating tumor hypoxic status and outcome in the preclinical and clinical settings. Front Oncol. 2017;7:10.","journal-title":"Front Oncol"},{"issue":"4","key":"1375_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2967\/jnumed.115.166579","volume":"57","author":"R Iqbal","year":"2016","unstructured":"Iqbal R, Kramer GM, Verwer EE, Huisman MC, de Langen AJ, Bahce I, et al. Multiparametric analysis of the relationship between tumor hypoxia and perfusion with \u00b9\u2078F-fluoroazomycin arabinoside and \u00b9\u2075O-H\u2082O PET. Journal of nuclear medicine\u202f: official publication, Society of Nuclear Medicine. 2016;57(4):530\u20135.","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"issue":"2","key":"1375_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/bjc.2014.610","volume":"112","author":"IN Fleming","year":"2015","unstructured":"Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112(2):238\u201350.","journal-title":"Br J Cancer"},{"issue":"11","key":"1375_CR26","first-page":"1851","volume":"45","author":"M Bruehlmeier","year":"2004","unstructured":"Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. Journal of nuclear medicine\u202f: official publication, Society of Nuclear Medicine. 2004;45(11):1851\u20139.","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"issue":"1","key":"1375_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00330-020-07067-2","volume":"31","author":"JC Carmona-Bozo","year":"2021","unstructured":"Carmona-Bozo JC, Manavaki R, Woitek R, Torheim T, Baxter GC, Carac\u00f2 C, et al. Hypoxia and perfusion in breast cancer: simultaneous assessment using PET\/MR imaging. Eur Radiol. 2021;31(1):333\u201344.","journal-title":"Eur Radiol"},{"issue":"7","key":"1375_CR28","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2967\/jnumed.116.188649","volume":"58","author":"M Grkovski","year":"2017","unstructured":"Grkovski M, Sch\u00f6der H, Lee NY, Carlin SD, Beattie BJ, Riaz N, et al. Multiparametric imaging of tumor hypoxia and perfusion with (18F)-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med. 2017;58(7):1072\u201380.","journal-title":"J Nucl Med"},{"issue":"1","key":"1375_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","volume":"21","author":"AA der Van Veldt","year":"2012","unstructured":"der Van Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012;21(1):82\u201391.","journal-title":"Cancer Cell"},{"key":"1375_CR30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00208","volume":"3","author":"AA van der Veldt","year":"2013","unstructured":"van der Veldt AA, Smit EF, Lammertsma AA. Positron emission tomography as a method for measuring drug delivery to tumors in vivo: the example of [(11C)docetaxel. Front Oncol. 2013;3:208.","journal-title":"Front Oncol"},{"issue":"2","key":"1375_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 2","key":"1375_CR32","doi-asserted-by":"publisher","first-page":"s11","DOI":"10.2967\/jnumed.122.264870","volume":"64","author":"J Knuuti","year":"2023","unstructured":"Knuuti J, Tuisku J, K\u00e4rpijoki H, Iida H, Maaniitty T, Latva-Rasku A, et al. Quantitative perfusion imaging with Total-Body PET. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2023;64(Suppl 2):s11\u20139.","journal-title":"Soc Nuclear Med"},{"issue":"3","key":"1375_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12149-025-02014-x","volume":"39","author":"O Rainio","year":"2025","unstructured":"Rainio O, Kl\u00e9n R. Compartmental modeling for blood flow quantification from dynamic 15O-water PET images of humans: a systematic review. Ann Nucl Med. 2025;39(3):231\u201346.","journal-title":"Ann Nucl Med"},{"issue":"13","key":"1375_CR34","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1007\/s00259-021-05461-6","volume":"48","author":"R Slart","year":"2021","unstructured":"Slart R, Tsoumpas C, Glaudemans A, Noordzij W, Willemsen ATM, Borra RJH, et al. Long axial field of view PET scanners: a road map to implementation and new possibilities. Eur J Nucl Med Mol Imaging. 2021;48(13):4236\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1375_CR35","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2967\/jnumed.124.269409","volume":"66","author":"A \u00c5hlstr\u00f6m","year":"2025","unstructured":"\u00c5hlstr\u00f6m A, Lindstr\u00f6m E, Maaniitty T, Iida H, K\u00e4rpijoki H, S\u00f6rensen J, et al. Automated total-body perfusion imaging with (15)O-water PET using basis functions and organ-specific model selection. J Nucl Med. 2025;66(8):1307\u201313.","journal-title":"J Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01375-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:20:11Z","timestamp":1781626811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01375-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01375-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7908120\/v1","asserted-by":"object"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board (Central Denmark Region Committees on Health Research Ethics (1-10-72-238-19)) and performed in accordance with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects signed an informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publication"}},{"value":"MRJ, NLC, MH, KB and MB declare that they have no competing interests. JS and LPT hold shares in MedTrace, H\u00f8rsholm, Denmark.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"23"}}